NASDAQ$DAWN
Day One Biopharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported a net income of $37.0 million and OJEMDA net product revenues of $20.1 million.
Day One Biopharmaceuticals, Inc. announced its third quarter 2024 financial results, featuring $20.1 million in OJEMDA net product revenue and $73.7 million in license revenue. The company ended the quarter with $558.4 million in cash, cash equivalents and short-term investments.
- OJEMDA net product revenues were $20.1 million for the third quarter of 2024.
- License revenue from the sale of ex-U.S. commercial rights for tovorafenib was $73.7 million for the third quarter of 2024.
- Net income totaled $37.0 million for the third quarter of 2024.
- Cash, cash equivalents and short-term investments totaled $558.4 million as of September 30, 2024.
Headline financials
Revenue & EPS history
Day One · Revenue · Quarterly
$93.8M
Forward guidance
The company plans to continue to drive growth by advancing programs and pipeline, including DAY301, a potential first-in-class ADC targeting PTK7 expected to be in the clinic in the coming months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-1.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+1.2%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+23.6%
Q2 2022
Best reaction
-16.6%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.2% | -13.9% | +78.0% | |
| Q3 2025 | +0.0% | +3.7% | +34.8% | |
| Q2 2025 | -15.4% | -14.2% | +9.7% | |
| Q1 2025 | -9.6% | -5.9% | +2.9% | |
| Q4 2024 | -16.5% | -30.2% | -31.7% | |
| Q3 2024 | +2.6% | +3.2% | -2.9% | |
| Q2 2024 | -6.8% | -9.4% | -11.0% | |
| Q1 2024 | -0.5% | -6.8% | -23.9% | |
| Q4 2023 | +14.5% | +15.0% | +4.0% | |
| Q3 2023 | -3.1% | -11.1% | -3.7% | |
| Q2 2023 | +1.3% | +4.3% | +9.6% | |
| Q1 2023 | +12.7% | +10.3% | +7.3% | |
| Q4 2022 | +5.3% | -4.2% | -32.8% | |
| Q3 2022 | +2.7% | +10.6% | +14.3% | |
| Q2 2022 | +23.6% | +18.9% | +24.4% | |
| Q1 2022 | +8.5% | +21.8% | -6.1% | |
| Q4 2021 | +3.7% | -3.8% | -6.9% | |
| Q3 2021 | -9.2% | -15.7% | -31.7% | |
| Q2 2021 | -16.6% | -7.6% | -5.2% | |
| Q4 2020 | -16.6% | -7.6% | -5.2% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro